Edwards Lifesciences Corporation (EW) is a medical device maker specializing in structural heart therapies, including the SAPIEN family of transcatheter aortic valve replacement systems and the PASCAL and EVOQUE mitral and tricuspid products. After trading as high as about $96.29 over the past year, the stock sits near $90.74, leaving $100 as an obvious, widely discussed psychological milestone. That level also aligns closely with Wall Street's consensus twelve-month target, which hovers near $100, making it a natural focal point for investors searching for an EW stock price target.
Edwards has refocused its business around structural heart disease after selling its Critical Care product group to Becton, Dickinson in 2024. That strategic shift has sharpened the growth profile. Second-quarter 2026 revenue rose 13.6% year over year to $1.74 billion, with adjusted operating margin expanding to 30%. The company's flagship TAVR segment remains the largest driver, while the faster-growing TMTT division delivered sales growth near 45% at constant currency, as adoption of PASCAL, EVOQUE, and SAPIEN M3 broadened across mitral and tricuspid procedures.
Several factors support the possibility that EW could climb toward $100. Management raised 2026 companywide constant-currency revenue growth guidance to 10–11% and lifted its TMTT sales outlook, while continuing to target roughly $2 billion in TMTT revenue by 2030. On the policy side, a proposed update to Medicare's TAVR coverage framework could reduce hospital and registry burdens, broaden patient eligibility, and enlarge the addressable population—developments analysts have cited as supportive of higher targets.
Recent analyst activity has been notably constructive. JPMorgan upgraded the stock to Overweight with a $100 target, while UBS initiated coverage with a $110 target. Other firms, including Piper Sandler and Stifel, have raised their targets into the $101–$105 range. The broad consensus points to a "Buy" rating and an average price target near $100–$101, suggesting the Street already views $100 as attainable over a twelve-month horizon.
From a technical analysis standpoint, the immediate hurdle is the prior 52-week high around $96.29. A decisive move above that level would clear the last major supply zone before the psychologically significant $100 mark. On the downside, the $85–$86 area has served as a support level during recent pullbacks, and the lower end of the 52-week range near $72 provides deeper support. The overall long-term trend structure has improved as the stock has recovered from its 2024 lows, but EW has not yet broken decisively into new multi-year highs.
The primary obstacle is valuation. EW trades at a premium forward price-to-earnings multiple—around 28–29 times—relative to both its sector and the broader S&P 500, leaving less room for error if execution disappoints. Competition also looms: large cardiovascular rivals continue to invest aggressively, and a prior benefit from a competitor's exit in Europe is expected to roll off. Foreign-exchange headwinds, litigation, tariffs, and reimbursement uncertainty add further execution risk. If TAVR growth stalls or TMTT adoption slows, the path to $100 would become considerably more difficult.
Traders monitoring Edwards Lifesciences and thousands of other securities can use Tickeron's AI Daily Buy/Sell Signals to stay aligned with shifting conditions. The product uses artificial intelligence to continuously scan stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market behavior, technical patterns, and AI-driven analysis. These signals can help traders discover new opportunities, monitor existing positions, and identify emerging market trends more efficiently than manual review alone. For investors tracking whether EW can reach $100, this type of automated monitoring offers a practical way to follow changing momentum as it develops.
A move to $100 for Edwards Lifesciences appears realistic but not assured. The strongest supporting factors are reaccelerating TAVR growth, rapid TMTT expansion, and a consensus analyst price target that already sits near the $100 mark. The primary risks are a demanding valuation and intensifying competition, which leave limited margin for setbacks. Investors should watch TAVR and TMTT revenue trends, developments in Medicare coverage policy, and whether the stock can break above its prior high near $96 before setting its sights on $100.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, EW has been loosely correlated with ISRG. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if EW jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To EW | 1D Price Change % |
|---|---|---|
| EW | 100% | -3.54% |
| Medical/Nursing Services industry (141 stocks) | 0% Poorly correlated | -0.97% |
| Health Services industry (242 stocks) | -0% Poorly correlated | -0.92% |